ASCO Preview on Breast Cancer
A review of camizestrant's upcoming ODAC meeting
Challenges and limitations associated with bispecific ADCs
The recent debate around trastuzumab deruxtecan (T-DXd) resistance has quietly split into two camps:…
Review of 10 key early and late stage trials, including Relay and Scorpion's mutant selective PI3Kα inhibitors
The hunt for novel payloads for ADCs continues apace
SITC25 Roundup with some suprising findings to take note of
Targeting KRAS G12D has already seen some shakeout – can the next generation agents prove successful?
A look at emerging ADCs in many shapes and flavours, including dual and novel payload versions
The trouble with translating Chinese trials to Western populations
A classic comeback story
New developments in metastatic and early stage breast cancer from Berlin
Highlights and lowlights from Day 1 of ESMO25
A look at some early stage IO agents and small molecules coming down the pike
Standing out from the crowd – 6 ADC trends to watch out for at ESMO
